Discontinue medication if any of the following situations occur:
When to Discontinue Treatment
Reversible Posterior Leukoencephalopathy Syndrome (RPLS)
Medication must be stopped immediately if symptoms of RPLS occur (including neurological abnormalities such as headache, seizures, confusion, or visual impairment), regardless of whether they are accompanied by elevated blood pressure.
Uncontrolled Hypertension
If hypertension remains uncontrollable even after using anti-hypertensive drugs and adjusting the Axitinib dosage, the medication should be suspended. Once blood pressure returns to normal, treatment may be restarted at a lower dose. In the event of a hypertensive crisis, the medication must be permanently discontinued.
Bleeding and Contraindications
This drug is contraindicated in patients with untreated brain metastases or a recent history of gastrointestinal bleeding. If a bleeding event occurs that requires medical intervention, medication must be suspended.
Cardiac Dysfunction
Cardiac function should be continuously monitored during treatment. If symptoms of heart failure develop, permanent termination of treatment may be necessary.
Surgery and Wound Healing
Discontinue medication at least 2 days prior to scheduled non-emergency surgery. After major surgery, the medication should be withheld for at least 2 weeks and only resumed once the wound is fully healed.
Proteinuria and Renal Issues
When moderate to large amounts of protein are detected in the urine, the dosage should be reduced or suspended. If the condition develops into nephrotic syndrome, the medication must be permanently discontinued.
Important Note
During the course of treatment, various physical indicators must be reviewed regularly. Any physical discomfort should be reported to a doctor immediately. The physician will evaluate whether to adjust the medication regimen or take other medical measures based on the specific situation.
Drug Interactions with Axitinib
Axitinib is primarily metabolized by CYP3A4/5 enzymes in the liver (enzymes responsible for breaking down drug components in the body). Additionally, its solubility is affected by gastric acid concentration; a decrease in gastric acid leads to reduced drug solubility.
Strong CYP3A4/5 Inhibitors (e.g., ketoconazole)
When used concurrently, the dosage of Axitinib must be reduced by half.
Strong CYP3A4/5 Inducers (e.g., rifampin)
Combination use should generally be avoided. If a strong inducer must be used, the dosage of Axitinib should be gradually increased under medical supervision.
